Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4RMB0
|
|||
| Drug Name |
3PO
|
|||
| Synonyms |
18550-98-6; 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3PO; 13309-08-5; CHEMBL3105848; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one; (E)-3-(Pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; SCHEMBL196639; 3-PO; (E)-3PO;3PO; CHEBI:144367; BCP34641; ZINC3997313; BDBM50445948; s7639; 3PO, >=98% (HPLC); AKOS025142053; CCG-266648; CS-5491; SB17190; NCGC00386709-03; AS-55969; HY-19824; AB00079158-01; SR-01000203323; SR-01000203323-1; 2-Propen-1-one, 3-(3-pyridinyl)-1-(4-pyridinyl)-; 3-(pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (2E)-3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one (3PO); (2E)-3-(PYRIDIN-3-YL)-1-(PYRIDIN-4-YL)PROP-2-EN-1-ONE
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H10N2O
|
|||
| Canonical SMILES |
C1=CC(=CN=C1)C=CC(=O)C2=CC=NC=C2
|
|||
| InChI |
1S/C13H10N2O/c16-13(12-5-8-14-9-6-12)4-3-11-2-1-7-15-10-11/h1-10H/b4-3+
|
|||
| InChIKey |
UOWGYMNWMDNSTL-ONEGZZNKSA-N
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:144367
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Renal carcinoma antigen NY-REN-56 (PFKFB3) | Target Info | Antagonist | [2] |
| BioCyc | Fructose 2,6-bisphosphate synthesis | |||
| KEGG Pathway | Fructose and mannose metabolism | |||
| HIF-1 signaling pathway | ||||
| AMPK signaling pathway | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | Glycolysis | |||
| WikiPathways | Metabolism of carbohydrates | |||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis. Lab Invest. 2020 Jun;100(6):801-811. | |||
| REF 2 | CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis. Gastroenterology. 2020 Jul;159(1):273-288. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.